348 related articles for article (PubMed ID: 32167223)
1. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Welk B; McArthur E
BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
[TBL] [Abstract][Full Text] [Related]
2. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Matta R; Gomes T; Juurlink D; Jarvi K; Herschorn S; Nam RK
Eur Urol Focus; 2022 Sep; 8(5):1433-1440. PubMed ID: 34742663
[TBL] [Abstract][Full Text] [Related]
3. Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study.
Park JS; Choi SB; Jang WS; Kim J; Ham WS
Eur Urol Focus; 2024 Feb; ():. PubMed ID: 38388215
[TBL] [Abstract][Full Text] [Related]
4. Are anticholinergic medications used for overactive bladder associated with new onset depression? A population-based matched cohort study.
Welk B; McArthur E
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1710-1714. PubMed ID: 33015899
[TBL] [Abstract][Full Text] [Related]
5. The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications.
Welk B; Etaby K; McArthur E; Chou Q
Neurourol Urodyn; 2022 Jan; 41(1):348-356. PubMed ID: 34719044
[TBL] [Abstract][Full Text] [Related]
6. Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
Minhas R; Tadrous M; Elterman D; Gomes T
Neurourol Urodyn; 2018 Jun; 37(5):1693-1700. PubMed ID: 29682790
[TBL] [Abstract][Full Text] [Related]
7. Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database.
Malcher MF; Droupy S; Berr C; Ziad A; Huguet H; Faillie JL; Serrand C; Mura T
J Urol; 2022 Oct; 208(4):863-871. PubMed ID: 35686842
[TBL] [Abstract][Full Text] [Related]
8. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
9. The cognitive effect of anticholinergics for patients with overactive bladder.
Welk B; Richardson K; Panicker JN
Nat Rev Urol; 2021 Nov; 18(11):686-700. PubMed ID: 34429535
[TBL] [Abstract][Full Text] [Related]
10. Yearly Trends of Overactive Bladder Medication Usage.
Chua KJ; Patel HV; Tabakin A; Srivastava A; Doppalapudi SK; Hyams E; Tunuguntla HSGR
Urol Pract; 2021 Sep; 8(5):546-554. PubMed ID: 37145398
[TBL] [Abstract][Full Text] [Related]
11. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
12. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
13. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Lua LL; Pathak P; Dandolu V
Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
[TBL] [Abstract][Full Text] [Related]
14. Persistence and Adherence of Anticholinergics and Beta-3 Agonist for the Treatment of Overactive Bladder: Systematic Review and Meta-Analysis, and Network Meta-Analysis.
Song YS; Lee HY; Park JJ; Kim JH
J Urol; 2021 Jun; 205(6):1595-1604. PubMed ID: 33207141
[TBL] [Abstract][Full Text] [Related]
15. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Ju R; Garrett J; Wu JM
Int Urogynecol J; 2014 Apr; 25(4):479-84. PubMed ID: 24158462
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of providers who prescribed only anticholinergic medications for overactive bladder in 2020.
Carr DN; Macharia A; Hacker MR; Winkelman WD
Am J Obstet Gynecol; 2023 Sep; 229(3):316.e1-316.e7. PubMed ID: 37244459
[TBL] [Abstract][Full Text] [Related]
17. Inequities in Filled Overactive Bladder Medication Prescriptions in the US.
Luchristt D; Bretschneider CE; Kenton K; Simon M; Brown O
JAMA Netw Open; 2023 May; 6(5):e2315074. PubMed ID: 37223899
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Anticholinergic Use for Overactive Bladder on Cognitive Changes in Adults with Normal Cognition, Mild Cognitive Impairment, or Dementia.
Welk B; McClure JA
Eur Urol Open Sci; 2022 Dec; 46():22-29. PubMed ID: 36506252
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
20. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
Krhut J; Gärtner M; Petzel M; Sykora R; Nemec D; Tvrdik J; Skoupa J
Scand J Urol; 2014 Feb; 48(1):79-83. PubMed ID: 23870042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
